What is the latest status of the project “Celltrion US Manufacturing Facility Expansion”?

The status recorded for “Celltrion US Manufacturing Facility Expansion” is planned.

What is the budget and commercial profile for the project “Celltrion US Manufacturing Facility Expansion”?

Taiyo normalizes the budget of “Celltrion US Manufacturing Facility Expansion” to USD 478000000.

Where can I verify the source and access all details for “Celltrion US Manufacturing Facility Expansion”?

This Taiyo project page references Fierce Pharma along with the original URL (https://www.fiercepharma.com/manufacturing/celltrion-jacks-us-investment-plan-478m-outlay-upgrade-former-lilly-plant). Taiyo standardizes official data into a consistent, searchable project profile.

Celltrion US Manufacturing Facility Expansion

Sector: Commercial • Location: Branchburg, New Jersey, United States

Source: Fierce Pharma

Project

Planned

Celltrion plans to invest $478 million to upgrade the active pharmaceutical ingredient (API) manufacturing facility in Branchburg, New Jersey, which it acquired from Eli Lilly. The expansion will add six 11,000-liter bioreactors in two phases, increasing total production capacity to 132,000 liters. The first phase is expected to complete in three years. Celltrion is also considering building an ad

Status: Prospective
Sector: Commercial, Manufacturing (Industrial)
Location: Branchburg, New Jersey, United States of America
Updated: 22 Jul 2026
Source: Fierce Pharma

ConstructChat

Ask ConstructChat about Celltrion US Manufacturing Facility Expansion

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information

4 Q

The project “Celltrion US Manufacturing Facility Expansion” is an infrastructure initiative in the Commercial sector, located in Branchburg, New Jersey, United States. Taiyo aggregates data on it from Fierce Pharma.

Participants

Not available for this record.

Status

Original status	planned
Taiyo status	Prospective
Taiyo last update	2026-07-22

Contact

Not available for this record.

Description

Description	Celltrion plans to invest $478 million to upgrade the active pharmaceutical ingredient (API) manufacturing facility in Branchburg, New Jersey, which it acquired from Eli Lilly. The expansion will add six 11,000-liter bioreactors in two phases, increasing total production capacity to 132,000 liters. The first phase is expected to complete in three years. Celltrion is also considering building an additional manufacturing facility on available land at the site.
Original sector	Manufacturing
Budget

Location

Country	United States of America (USA)
State	New Jersey
City	Branchburg

Source

Source	Fierce Pharma
URL

More Details

Record type	Project
Sector	Commercial, Manufacturing (Industrial)
Article published date	2025-11-22

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

Every detail on this project
News and media coverage
Technical research

View all details

Free account · no card · lands you back on this project

Celltrion US Manufacturing Facility Expansion

Ask ConstructChat about Celltrion US Manufacturing Facility Expansion

Project Information FAQ

Project Information

Research

View all details

More Commercial projects in United States